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Objective: A significant number of patients have coronary artery disease that is not
amenable to traditional revascularization. Prospective, randomized clinical trials
have demonstrated therapeutic benefits with transmyocardial laser revascularization
in this cohort. The molecular mechanisms underlying this therapy, however, are
poorly understood. The focus of this study was evaluation of the proposed vasculo-
genic mechanisms involved in transmyocardial laser revascularization.
Methods: Male Yorkshire pigs (30–35 kg, n 5 25) underwent left thoracotomy
and placement of ameroid constrictors around the proximal left circumflex coronary
artery. During the next 4 weeks, a well-defined region of myocardial ischemia devel-
oped, and the animals underwent a redo left thoracotomy. The animals were randomly
assigned to sham treatment (thoracotomy only, control, n 5 11) or transmyocardial
laser revascularization of hibernating myocardium with a holmium:yttrium-alumi-
num-garnet laser (n 5 14). After an additional 4 weeks, the animals underwent
median sternotomy, echocardiographic analysis of wall motion, and hemodynamic
analysis with an ascending aortic flow probe and pulmonary artery catheter. The
hearts were explanted for molecular analysis.
Results: Molecular analysis demonstrated statistically significant increases in the
proangiogenic proteins nuclear factor kB (426 27 intensity units vs 5916 383 inten-
sity units, P 5 .03) and angiopoietin 1 (0 6 0 intensity units vs 241 6 87 intensity
units, P5 .003) relative to sham control values with transmyocardial laser revascular-
ization within the ischemic myocardium. There were also increases in vasculogenesis
(18.8 6 8.7 vessels/high-power field vs 31.4 6 10.2 vessels/high-power field,
P 5 .02), and perfusion (0.028 6 0.009 mm3 blood/mm3 tissue vs 0.044 6 0.004
mm3 blood/mm3 tissue, P 5 .01). Enhanced myocardial viability was demonstrated
by increased myofilament density (40.7 6 8.5 cardiomyocytes/high-power field vs
50.86 7.5 cardiomyocytes/high-power field, P5 .03). Regional myocardial function
within the treated territory demonstrated augmented contractility. Global hemody-
namic function was significantly improved relative to the control group with transmyo-
cardial laser revascularization (cardiac output 2.1 6 0.2 L/min vs 2.7 6 0.2 L/min,
P5 .007, mixed venous oxygen saturation 64.7%6 3.6% vs 76.1%6 3.4%,P5 .008).
Conclusion: Transmyocardial laser revascularization with the holmium-YAG laser
enhances perfusion, with resultant improvement in myocardial contractility.
T
he latest ‘‘Heart Disease and Stroke Statistics—2007 Update’’ from the Amer-
ican Heart Association estimates that there are 15.8 million Americans with
coronary artery disease.1 We have made significant advances in our ability
to treat ischemic myocardial disease with both coronary artery bypass grafting and
percutaneous coronary intervention. Millions of Americans, however, have intracta-
ble angina and heart failure not amenable to revascularization with coronary artery
bypass grafting or percutaneous coronary intervention.
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EPC 5 endothelial progenitor cell
Ho:YAG 5 holmium:yttrium-aluminum-garnet
hpf 5 high-power field
iu 5 intensity units
NFkB 5 nuclear factor kB
TMR 5 transmyocardial laser revascularization
VEGF 5 vascular endothelial growth factor
Transmyocardial laser revascularization (TMR) uses laser
energy to create transmural channels through the ventricular
free wall. This therapy originally attempted to replicate blood
flow in the reptilian heart, in which direct myocardial sinu-
soids provide oxygenated blood directly from the left ventri-
cle.2 Numerous randomized, prospective clinical trials have
shown significant improvements in angina, rehospitaliza-
tions, function, and event-free survival after TMR.3-7 The So-
ciety of Thoracic Surgeons working group on evidence-based
surgery has recommended TMR as therapy for patients with
refractory angina who cannot undergo revascularization.8
The lased myocardial channels are not patent 2 weeks after
TMR according to histologic evaluation, raising the question
of the true molecular mechanism underlying the clinical im-
provements.9-11 Previous studies have provided preliminary
data for TMR-mediated vasculogenesis. These studies used
basic, inferential assays to study vasculogenesis. With a por-
cine model of ischemic heart failure, we sought to elucidate
clearly and definitively the changes in molecular biology
and cellular and global physiology induced by transmyocar-
dial holmium:yttrium-aluminum-garnet (Ho:YAG) laser re-
vascularization. Our study focused on endothelial
progenitor cell (EPC) upregulation, vasculogenic chemokine
expression, neovasculogenesis, and enhanced perfusion as
mediators of improved contractility after TMR.
Materials and Methods
Animal Care and Biosafety
Male Yorkshire pigs (30–35 kg) were obtained from Archer Farms
(Darlington, Md). This protocol was approved by the Institutional
Animal Care and Use Committee of the University of Pennsylvania.
All animals received humane care and treatment in accordance with
the ‘‘Guide for the Care and Use of Laboratory Animals’’ (www.
nap.edu/catalog/5140.html). Measurements were performed by
blinded investigators.
Induction of Myocardial Dysfunction
Male Yorkshire pigs were administered ketamine, medetomidine
hydrochloride (INN medetomidine), and thiopental, were endotra-
cheally intubated, and were maintained on inhaled isoflurane
(1.5%–3.0%). A left fourth interspace thoracotomy was performed
to expose the lateral left ventricle. The atrioventricular groove was
stabilized, and the proximal left circumflex coronary artery was dis-
sected free. A titanium ameroid constrictor (2.5–3.0 mm; Research284 The Journal of Thoracic and Cardiovascular Surgery c FeInstruments SW, Escondido, Calif) was placed around the vessel to
provide a close fit without compromising the lumen (n 5 25). The
chest was closed in three layers over a temporary 28F thoracostomy
tube, and the animal was allowed to recover. The ameroid constric-
tor occluded the circumflex coronary artery during the course of 4
weeks, thereby causing wall motion abnormalities and myocardial
dysfunction to develop.12-14
Four weeks after the initial operation, the animals underwent
a redo left thoracotomy, and the ventricle was dissected free of ad-
hesions. At this stage, the hearts grossly manifested myocardial dys-
function consistent with myocardial ischemia in the circumflex
distribution. Wall motion abnormality was confirmed with echocar-
diography. The areas of ischemia and of wall motion abnormality,
a measure of ischemia, were equivalent between the groups. An
oximetric continuous cardiac output pulmonary arterial catheter
(Edwards Lifesciences, Irvine, Calif) was placed though the left in-
ternal jugular vein, and an arterial line was inserted to confirm equiv-
alent baseline myocardial function. Statistical analysis demonstrated
no differences between control and TMR groups in baseline cardiac
output (3.8 6 0.3 L/min vs 3.7 6 0.3 L/min, difference not signif-
icant), mixed venous oxygen saturation (69.6%6 1.9% vs 69.6%6
5.2%, difference not significant), central venous pressure (12.5 6
0.4 mm Hg vs 11.4 6 1.0 mm Hg, difference not significant),
mean pulmonary arterial pressure (25.3 6 0.9 mm Hg vs 24.4 6
1.5 mm Hg, difference not significant), heart rate (85.3 6 11.6
beats/min vs 87.4 6 3.6 beats/min, difference not significant), or
mean arterial pressure (78.8 6 5.2 mm Hg vs 76.4 6 5.7 mm Hg,
difference not significant). The animals were randomly assigned
to undergo either sham operation (thoracotomy alone) or TMR.
The animals in the sham group (n 5 11) were then closed and al-
lowed to recover. The TMR subset (n 5 14) underwent revascular-
ization with a SolarGen 2100s Ho:YAG TMR laser with a SoloGrip
III handpiece (Cardiogenesis Corporation, Irvine, Calif). A total of
12 TMR channels (8–10 pulses/channel) at a density of 1/cm2
were created in the ischemic lateral wall. The Ho:YAG laser gener-
ates a 2.1-mm wavelength with a 200-ms pulse width (repetition rate
5 Hz, nominal power 7 W/channel, 1.4 J/pulse). The laser was used
at the same settings and with the same technique that are used clin-
ically and have been experimentally confirmed.3,4,15-17 A combina-
tion of change in pitch of the laser and a jet of blood from the channel
after TMR confirmed the creation of transmural channels.
There are three major lasers available for TMR, the carbon di-
oxide, Ho:YAG, and xenon-chloride excimer lasers. The excimer
laser, a cold, ultraviolet laser that creates channels by dissociation
of molecular bonds, is not used clinically in the United States.
The carbon dioxide and Ho:YAG lasers are infrared lasers that
use thermal ablation to create channels. The Ho:YAG lasers
pulsed thermoacoustic energy wave penetrates the tissue wider
than does the single-pulse high-powered carbon dioxide laser.
The degree of neovascularization after TMR has been shown to
directly correlate with the degree of laser-induced tissue inflam-
mation.
Eight weeks after initial surgery, the animals were anesthetized,
and a continuous cardiac output pulmonary arterial catheter and an
arterial line were placed. The heart was exposed through a median
sternotomy. The aortopulmonary window was dissected free, and
an ascending aortic flow probe (Transonic Systems, Inc, Ithaca,
NY) was placed to measure cardiac output. The flow probe usesbruary 2008
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measure of cardiac output than does a pulmonary arterial catheter.
Regional wall motion was analyzed with epicardial echocardiogra-
phy. The animals were then euthanized for molecular analysis. Not
all assays could be performed on all animals because of methodo-
logic constraints between assays (lectin angiography prevented he-
modynamic, Western blot, and immunocytochemical analyses).
Eight of 25 animals did not have hemodynamic measurements.
Flow Cytometric Analysis of Circulating EPC
Upregulation
Flow cytometric analysis was performed to evaluate upregulation of
circulating EPCs, the precursor cells purportedly responsible for
vasculogenesis. Forty-eight hours after either sham operation or
therapy with the TMR procedure, circulating blood was obtained
from the innominate vein. Red blood cell lysis was performed
with standard ammonium chloride lysis buffer. Cell viability was as-
sessed with 7-amino-actinomycin D (BD Biosciences, Franklin
Lakes, NJ) labeling. Circulating lymphocytes were labeled with
fluorescein isothiocyanate–conjugated anti-CD31 (Serotec, Ra-
leigh, NC), phycoerythrin–conjugated anti-CD133 (Miltenyi Biotec
Inc, Auburn, Calif), and allophycocyanin–conjugated anti-vascular
endothelial growth factor (VEGF) receptor 2 (BD Biosciences) an-
tibodies. Appropriate lymphocyte compensation controls were used.
EPCs were defined as CD312CD1331VEGFR21 cells. Analysis
(n 5 2/group) was performed on 2 million cells per group (FACS
Calibur; BD Biosciences). EPC density is expressed as percentage
of circulating lymphocytes.18-21
Analysis of Myocardial Chemokine Expression
Nuclear factor kB (NFkB) plays a key role in stimulating vasculo-
genic mediators (VEGF, basic fibroblast growth factor), enhancing
vasculogenesis, and inducing key vasculogenic transcription fac-
tors.22-25 Angiopoietin 1, acting through the TIE2 receptor, stimu-
lates vasculogenesis and enhances stabilization and maturation of
vessels.26,27 We have sought to investigate alterations in these pro-
angiogenic transcription factors and proteins to elucidate the
mechanism of TMR. Myocardial sections were isolated from the is-
chemic territory of the left ventricle of both control and TMR group
animals and homogenizedwith amortar and pestle for protein extrac-
tion. Homogenized myocardial samples were suspended in Tissue
Protein Extraction Reagent (Pierce Chemical Company, Rockford,
Ill) with 1% Triton X-100 (The Dow Chemical Company, Midland,
Mich), protease inhibitors (Pierce), and phosphatase inhibitors
(Pierce). Protein concentrations were determined with the Bio-
Rad protein assay (Bio-Rad Laboratories) in triplicate. Myo-
cardial protein (50 mg/sample) was loaded on precast 4% to 12%
1,3-bis(tris[hydroxymethyl]methylamino)propane gels after dena-
turation in reducing sample buffer. Proteins were transferred to
0.2 mm polyvinylidene difluoride membranes (Invitrogen Corpora-
tion, Carlsbad, Calif) and subsequently blocked with 5% nonfat dry
milk in tris(hydroxymethyl)aminomethane–buffered saline solution.
Immunoblotting was performed with antibodies against either NFkB
(Abcam Inc, Cambridge,Mass) or angiopoietin 1 (Abcam). Labeling
for actin (Abcam) confirmed equivalent loading of protein in control
and TMR groups (25106 172 intensity units [iu] vs 23986 158 iu,
difference not significant). Protein levels were quantified with Scion
Image software v.4.0.3.2 (Scion Corporation, Frederick, Md).The Journal of ThoQuantification of Myocardial Angiogenesis
Myocardial vascular density was determined by labeling the myo-
cardial regions of the left circumflex territory for CD31, which is
found on mature, differentiated endothelial cells of vasculature.
Myocardial sections were fixed with acetone and blocked with 1%
bovine serum albumin and 10% normal goat serum. The sections
were treated overnight at 4C with mouse antirat CD31 antibody
(BD PharMingen, San Diego, Calif). Samples were washed and in-
cubated with goat antimouse fluorescein isothiocyanate–conjugated
antibody (Abcam) for 1 hour at room temperature. Immunocyto-
chemical vascular density analysis was performed in four fields
for each sample for remote and ischemic myocardium (203, Leica
DM5000B microscope, Leica Application Suite v2.2.0; Leica
Microsystems Inc, Deerfield, Ill).
Assessment of Myocardial Perfusion
Before each animal was euthanized, 500-mg/kg fluorescein-labeled
Lycopersicon esculentum (tomato) lectin (Vector Laboratories,
Inc, Burlingame, Calif) was injected into the superior vena cava
and allowed to circulate for 10 minutes. Tomato lectin binds to
the surface N-acetylglucosamine oligomers of endothelial cells lin-
ing perfused vessels.28 Direct contact of lectin with endothelial cells
is requisite for lectin labeling, so only perfused vessels are labeled.
After lectin perfusion, the hearts were explanted and snap frozen
in liquid nitrogen. Sequential sections were obtained with scanning
laser confocal microscopy through 100-mm thick myocardial sec-
tions of normal, remote, and ischemic myocardial regions.29
Three-dimensional reconstructions of the image stacks were created
with Volocity Software v.3.61 (Improvision Inc, Waltham, Mass).
Pixels delineating labeled vasculature and total tissue sections
were quantified, thereby allowing determination of total perfusion
per mass of myocardial tissue. Quantitation of the lectin-bound vas-
culature thus provided a direct measure of myocardial perfusion in
the form of a microvascular angiogram. Measurements were made
in two myocardial regions for each sample.
Assessment of Myocardial Viability
Analysis of myocardial viability was performed by quantifying
myocardial density. Myocardial thin sections (10 mm) were
counterstained with Masson trichrome stain to delineate myofila-
ment structure and function. Myofilament density (total cardiomyo-
cytes/high-power field [hpf]) was determined in five separate
ischemic myocardial regions in a 203 hpf as a measure of myocar-
dial density.29,30
Quantification of Myocardial Function
Myocardial regional contractile function was assessed with echocar-
diography (Phillips Sonos 5500 rev D, 8 MHz, 6 cm; Philips Med-
ical Systems North America, Shelton, Conn) 8 weeks after ameroid
placement. Wall motion score index was analyzed according to the
American Society of Echocardiography regional wall motion grad-
ing scale (1 normal, 2 hypokinetic, 3 akinetic, 4 dyskinetic, 5 aneu-
rysmal), whereby six regions were scored at the basal and
midpapillary level with parasternal short-axis views. The apex
was scored with parasternal long-axis visualization. Global wall mo-
tion score index was determined by the average of the 13 segments
analyzed. The hemodynamic benefits after therapy with TMRwould
be expected to be largely regional in nature. Therefore carefulracic and Cardiovascular Surgery c Volume 135, Number 2 285
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ity with epicardial echocardiography of the ischemic lateral wall.
Regional contractility of the lateral wall was determined at the mid-
papillary level with imaging along the short axis. Invasive hemody-
namic analysis was determined by continuous cardiac output
pulmonary arterial catheter, a femoral arterial catheter, and an as-
cending aortic flow probe (Transonic) placed around the aortic
root for Doppler analysis of cardiac output.
Data Analysis
Quantitative data are expressed as mean 6 SEM. Statistical signif-
icance was evaluated with the unpaired Student t test for comparison
between two means.Results
Upregulation of Circulating EPCs
Flow cytometric analysis demonstrated a significant increase
in the circulating CD312 CD1331VEGFR21 EPC density
48 hours after therapy with TMR relative to sham control
values (0.046% 6 0.02% total lymphocytes vs 0.017% 6
0.007% total lymphocytes, n 5 2/group]. By gating for the
CD312 subpopulation, we selected for the immature,
pluripotent EPC population. Viability analysis with 7-
amino-actinomycin D demonstrated minimal cell death. Rep-
resentative histogram and dot plots used in EPC identification
are demonstrated in Figure 1.Figure 1. Therapy with transmyocardial laser revascularization upregulates circulating CD312 CD1331VEGFR21
endothelial progenitor cells. Representative flow cytometric plots of circulating blood 48 hours after either sham
treatment (thoracotomy alone) or transmyocardial laser revascularization. A, Dot plots of forward and side scatter
determination of lymphocyte subpopulation; representative gate for lymphocytes is visualized. B, Histogram of 7-
amino-actinomycin D (7AAD) labeling of lymphocyte cell viability. C, Histogram representing a CD312 population.
Representative, gated viable, CD312 cell population is delineated. D and E, EPC density in representative animals
from sham (D) and transmyocardial laser revascularization (E) groups after gating for CD312 population, as deter-
mined by colabeling of CD133 and VEGFR2. Quantification of endothelial progenitor cell density demonstrates sig-
nificant increase relative to sham control in circulating CD312 CD1331VEGFR21 endothelial progenitor cells after
transmyocardial laser revascularization.
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Protein quantification with Western blot analysis demon-
strated a statistically significant increase in myocardial ex-
pression of NFkB after TMR relative to control (42 6 27 iu
vs 5916 383 iu, n5 4/sham, n5 6/TMR, P5 .03). Western
blotting demonstrated a dramatic increase in expression of
NFkBwithin the TMR-treated hibernating myocardium (Fig-
ure 2). This increase in the provasculogenic protein NFkB
implies a neovasculogenic effect of TMR.
Similarly, dramatic increases from control values in ex-
pressions of both the native angiopoietin 1 (0 6 0 iu vs
2416 87 iu, n5 4/sham, n5 6/TMR, P5 .003) and glyco-
sylated angiopoietin 1 (4606 194 iu vs 13946 436 iu, n5 4/
sham, n5 6/TMR,P5 .003) proteins were detected in the hi-
bernating myocardium after TMR. As with NFkB, there was
a dramatic increase in angiopoietin 1 expression in the TMR
group visible on the Western blot (Figure 2). Enhanced ex-
pression of angiopoietin 1 provides an indication of vasculo-
genesis, vascular maturation, and increased myocardial
viability.
TMR Enhancement of Myocardial Angiogenesis
Analysis of myocardial vascular density demonstrated a
statistically significant increase in vasculature within the
Figure 2. A, Western blot analysis of nuclear factor kB (NFk-B)
myocardial protein levels in sham and transmyocardial laser re-
vascularization (TMR) groups reveals dramatic upregulation after
TMR in hibernating myocardium. Nuclear factor kB was detected
at 116 kDa. B, Western blot analysis of angiopoietin 1 (Ang-1) ex-
pression in hibernating myocardium in sham and transmyocardial
laser revascularization groups demonstrates marked increase in
angiopoietin 1 after transmyocardial laser revascularization. Ex-
pression at 57 kDa corresponds to native angiopoietin 1, whereas
75-kDa band demonstrates expression of highly glycosylated form
of angiopoietin 1. Glycosylated angiopoietin 1 protein plays vital
role in vascular maturation. C, Western blot analysis of actin in
sham and transmyocardial laser revascularization groups con-
firms equivalent protein loading.The Journal of Thoterritory of the ischemic myocardium 4 weeks after TMR
(18.8 6 8.7 vessels/hpf vs 31.4 6 10.2 vessels/hpf, n 5 8/
group, P 5 .02). The enhanced vascular density correlated
with an increase in the circulating EPC population, implying
EPC-meditated vasculogenesis. On the other hand, it is pos-
sible that the enhanced vascularity was a manifestation of the
sprouting of new vasculature from preexisting blood vessels.
There was no difference in remote myocardial vascular den-
sity between control and TMR groups, demonstrating equiv-
alent baseline myocardial structure (60.96 2.1 vessels/hpf vs
60.3 6 2.9 vessels/hpf, difference not significant, n 5 8).
Representative images demonstrating immunofluorescent
CD311-labeled vasculature within the ischemic myocardial
territory are shown in Figure E1.
Augmented Myocardial Perfusion After TMR
Confocal microscopy allowed imaging of myocardial sec-
tions perfused with tomato lectin. Fluorescein-conjugated
lectin exclusively labels perfused vasculature. Therefore a
microvascular angiogram of only perfused vasculature is ob-
tained with this method. Analysis of remote myocardial vas-
culature did not reveal a difference in myocardial perfusion
between sham (n 5 2) and TMR (n 5 3) groups (0.064 6
0.008 mm3 blood/mm3 tissue vs 0.057 6 0.001 mm3 blood/
mm3 tissue, difference not significant). This served as an in-
ternal control, validating the assay and demonstrating similar
baseline perfusions in the two groups.
Qualitative analysis revealed a visually apparent increase
in hibernating myocardial perfusion after TMR (Figure 3).
Three-dimensional quantitative analysis of myocardial perfu-
sionwithin thehibernatingmyocardiumdemonstrated a statis-
tically significant increase in myocardial perfusion after TMR
(n 5 2) relative to the sham control group (n 5 3, 0.044 6
0.004 mm3 blood/mm3 tissue vs 0.028 6 0.009 mm3 blood/
mm3 tissue,P5 .01). In addition to demonstrating an increase
in perfusion following TMR, these data confirm the increase
in vasculature that was noted with CD31 vascular labeling.
The literature is inconclusive regarding changes in perfu-
sion after therapy with TMR. A lack of consistent improve-
ment in perfusion in the published literature may be due to
differences in therapeutic strategy, timing of measurement,
and sensitivity in measuring perfusion. Our study demon-
strated a nearly 50% increase in perfusion after TMR. As is
proved in this study, lectin angiography is a highly sensitive
measure that is capable of measuring changes in perfusion at
the microvascular level. Quantification of perfusion with mi-
crospheres after TMR with a carbon dioxide laser has also
demonstrated a dramatic increase in perfusion, corroborating
these findings.31
Enhanced Myocardial Viability After TMR
Qualitative analysis of myocardial sections demonstrated
a significant increase in myocardial viability after TMR (Fig-
ure 4). Quantitative analysis demonstrated a statisticallyracic and Cardiovascular Surgery c Volume 135, Number 2 287
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cular lectin angiogram demonstrates
enhanced myocardial perfusion after
therapy with transmyocardial laser re-
vascularization (TMR). Representative
angiograms from remote myocardium
and ischemic myocardium from animals
in sham and transmyocardial laser re-
vascularization groups are presented
(z-series, 253 oil magnification, Zeiss
LSM-510 Meta Confocal Microscope;
Carl Zeiss, Inc, Thornwood, NY). There
was no difference in remote myocardial
perfusion between sham and transmyo-
cardial laser revascularization groups. Perfusion of the ischemic myocardium was significantly increased after transmyocardial laser
revascularization. Orientation is presented in lower left corners. Red indicates y-axis; green indicates x-axis; blue indicates z-axis.significant increase in myofilament density in the hibernating
myocardium after TMR relative to the control group (50.86
7.5 myofilaments/hpf vs 40.7 6 8.5 myofilaments/hpf,
n 5 8/group, P 5 .03). Preservation of myocardium corre-
lated with increases in myocardial NFkB and angiopoietin
1 protein, in vasculature, and in perfusion.
TMR Improvement of Myocardial Function
Assessment of myocardial function demonstrated a statisti-
cally significant increase in hemodynamic function after ther-
apy with TMR relative to the sham group (Table 1). There
were marked improvements in both cardiac output and mixed
venous oxygen saturation after therapy. Moreover, there
were no differences in preload, afterload, heart rate, or hemo-
globin level.
TMR is regionally targeted to the ischemic myocardium,
rather than globally to the entire myocardial surface. As
such, one would expect the most significant improvements
in myocardial contractility to occur focally. Echocardiogra-
phy provides a means of studying regional myocardial
function. Myocardial contractile analysis demonstrated a sig-
nificant improvement in contractility of the ischemic lateral
wall of the left ventricle after TMR.Moreover, improvements
in global myocardial function were evidenced by significant
improvements in the global wall motion score index.Discussion
In this study, we demonstrated an increase in circulating
EPCs shortly after TMR. EPCs have the potential to differen-
tiate into endothelial cells and the support network necessary
for mature myocardial vasculature.18,32 They are stimulated
by several factors, including trauma, ischemia, and chemo-
kines. NFkB is a potent chemokine and transcription factor
that induces vasculogenesis.22-25 We have shown a dramatic
increase in NFkB levels after TMR, whereas this factor was
nearly absent in the sham subset. This increase in NFkB
levels may play a key role in targeting EPCs to the ischemic
myocardium, thereby enhancing EPC mediated vasculogen-
esis and perfusion. In human clinical trials, exogenous
administration of cultured EPCs has led to enhanced myocar-
dial perfusion, illustrating the role of EPCs in enhancing
myocardial blood flow.33-35
We also demonstrated an increase in angiopoietin 1
expression that correlated with increased vasculogenesis
and perfusion. Like the other TMR-upregulated proteins
(VEGF, basic fibroblast growth factor, and transforming
growth factor b), angiopoietin 1 may play a key role in in-
creasing myocardial perfusion and stimulating vascular mat-
uration after TMR.Myocardial angiopoietin 1 overexpression
after acute myocardial infarction has been associated with in-
creased myocardial survival, limited ventricular remodeling,Figure 4. Representative Masson tri-
chrome—stained images of myofila-
ment density within an ischemic
territory of the left circumflex coronary
artery of myocardium from sham and
transmyocardial laser revasculariza-
tion (TMR) Groups demonstrating en-
hanced myofilament density in latter
(original magnification 203). Red indi-
cates muscle; blue indicates collagen;
black indicates nuclei.
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function that result from TMR are likely a manifestation of
enhanced perfusion and an attenuation of hypoxia, with
resultant augmentation of myocardial viability.
As evidenced in this study, there is a marked and statisti-
cally significant preservation of myofilament mass after ther-
apy with TMR. The preservation of muscle mass directly
correlates with an increase in perfusion. Numerous studies
have demonstrated that myocardial ischemia mediates abnor-
mal cardiomyocyte metabolism, decoupling of energy con-
sumption and work generation, and enhanced apoptosis.
Ischemic myocardium receives limited perfusion, resulting
in limited contractility and increased propensity toward cell
death. By augmenting perfusion, we are enhancing viability
and the functional work that the muscle is able to perform.
In light of the tenuous viability of the ischemic myocardium
it is certainly possible that only moderate increases in perfu-
sion are required for dramatic increases in function. Restora-
tion of myocardial perfusion and reversal of ischemia, as is
seen experimentally in this study with TMR, play a critical
role in preserving myofilament density, in ventricular remod-
eling, and ultimately in maintaining myocardial function.
Clinical evidence for the protective effects of laser revas-
cularization has also been demonstrated. The largest random-
ized, multicenter, prospective study compared TMR with
a Ho:YAG laser with medical management alone for patients
with class IV angina. This study demonstrated reduction in
TABLE 1. Hemodynamic parameters 4 weeks after sham
thoracotomy or transmyocardial laser revascularization
therapy of ischemic myocardium in the left circumflex
coronary artery territory
Sham (n 5 8) TMR (n 5 9) P value
Heart rate (beats/min) 89.1 6 5.3 84.1 6 5.8 NS
Central venous
pressure (mm Hg)




21.0 6 2.1 22.5 6 1.1 NS
Mean arterial pressure
(mm Hg)
83.5 6 7.4 78.5 6 8.6 NS
Cardiac output (L/min) 2.1 6 0.2 2.7 6 0.2 .007
Hemoglobin (g/dL) 8.7 6 0.9 8.5 6 0.9 NS
Mixed venous oxygen
saturation (%)










2.1 6 0.2 1.3 6 0.4 .009
Values are mean 6 SEM. TMR, Transmyocardial laser revascularization;
NS, not significant. *A normal motion value is scored as 1.The Journal of Thoangina, improved exercise tolerance, and greater freedom
from cardiac events with TMR.4 Similarly, Frazier and col-
leagues5 reported a statistically significant improvement in
perfusion and a decrease in hospitalization after TMR with
a carbon dioxide laser relative to medical therapy.
There remains some controversy regarding the molecular
mechanism behind TMR’s success. Proposed alternate theo-
ries for the clinical improvements after TMR include placebo
effect, myocardial denervation, and local trauma.36,37 Im-
provements in perfusion that have been noted after TMR sug-
gest reversal of ischemia rather than denervation as the major
mediator of improved cardiac function. Histologic studies 6
months after TMR have demonstrated regeneration of the
myocardial sympathetic nerves. Physiologic assays evaluat-
ing efferent nerve conduction have demonstrated intact con-
duction after TMR, refuting denervation.38,39 Studies
evaluating laser TMR versus mechanical TMR have demon-
strated improvements in arteriogenesis and function only
after laser TMR, showing an effect with laser energy beyond
mechanical trauma.15,40
The body of literature on TMRhas included a combination
of carbon dioxide and Ho:YAG lasers. These studies are not
directly comparable. There is, however, a correlation be-
tween the two lasers in terms of beneficial improvements in
angiogenesis, myocardial perfusion, and function. The im-
provements noted with these lasers may be related to induc-
tion of inflammation to varying degrees.40 Although not
directly comparable, these studies thus can be used for global
assessment of changes in molecular pathways and cellular
physiology after laser revascularization.
Combining clinical data with our mechanistic findings,
beginning with the analysis of acute effects on a molecular
level, providing insight into the findings of enhanced vascu-
logenesis, perfusion, viability, and function after TMR, pro-
vides strong evidence to support TMR to treat myocardial
ischemia not amenable to coronary artery bypass grafting
or percutaneous coronary intervention. In the setting of iso-
lated TMR, therapy may be administered by robotic or thor-
acoscopic41 means, thereby reducing postprocedure
recovery. In the future, the combination of TMR with either
EPC or cytokine delivery (stromal cell–derived factor 1a,
VEGF, basic fibroblast growth factor) may provide a robust
EPC-mediated vasculogenic signal to enhance perfusion
further and reverse ischemia.
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Discussion
Dr FrankW. Sellke (Boston, Mass). TMR was found several years
ago to improve perfusion and function in animals, yet most clinical
trials have had negative or barely positive results. Do you think you
are comparing TMR with no TMR in a clinically relevant model?
We don’t do TMR on patients that don’t have coronary disease or
hypercholesterolemia or other risk factors for vascular disease.
Would you have seen the same changes had you used a model
with endothelial dysfunction and vascular disease?
Dr Atluri. I believe we would have. The goal in this study is that
wewere trying to create a region of myocardial ischemia, a true region
of myocardial hypocontractility. I think the key is that we are looking
at regional dysfunction within our area of interest. Yes, therapy did
create a difference in this model. What we were basically trying to
replicate is not necessarily the global dysfunction but the regional
contractile dysfunction and malperfusion that we are trying to treat.
In human beings, there may be an entire left ventricular region with
endothelial dysfunction and arteriosclerosis, compromising the entire
wall. What we are trying to do is replicate dysfunction in just one re-
gion inwhich the ameroid is placed.We focused our studies on study-
ing this area and also on studying the regional hemodynamic benefits.
Dr Keith B. Allen (Indianapolis, Ind). This was an elegant pre-
sentation, and I enjoyed it. You have shownmicrovascular improve-
ment at the cellular level. I think this explains some of the clinical
findings with regard to the last question, where insensitive tests
such as thallium have been used previously to detect improvement
in perfusion. With a 12% to 15% error rate, it is easy to see why
changes at the cellular level may not necessarily be detected. You
have nicely demonstrated with DNA and cellular analysis that
TMR serves as a biomechanical trigger, with upregulation of the
myocytes surrounding the border zone of the laser channel. We
have hypothesized that this is a fertile area for enhanced angiogen-
esis by the addition of biologic materials, either PRP, stem cells, or
things like VEGF and basic fibroblast growth factor. Do you have
plans to carry on further studies looking at that possibility?
Dr Atluri.We thought this as sort of a two-step process. First, is
TMR usable? I think we have evidence that it is in fact usable. I have
enjoyed reading your articles in the past, and clearly I know that you
believe in the utility of TMR.The Journal of ThoI believe the process behind TMR, as you elucidated, is probably
related to inflammation. In this study, inflammation without gross
tissue destruction has been evidenced. For example, you double
TMR channels from 1 to 2 channels/cm2, you get too much destruc-
tion; decrease it, and you don’t have enough inflammation for ther-
apy. The moment you have inflammation, you upregulate cytokines
and DNA transcription factors. After that, you get enhanced micro-
vascular perfusion, which is the key. It is not the development of the
large vessels or the big highways but rather the small microvascula-
ture that enhances perfusion.
The other way to augment that perfusion in addition to upregu-
lating the body’s own reparative system is to enhance angiogenesis
with either additional cytokines or cell transplantation. We are look-
ing into these adjunctive therapies as sort of a second stage of inves-
tigation.
Dr Frank Bowen (Boston, Mass). I have two questions. First,
did you find in the animals that underwent TMR that there was pres-
ervation of global systolic function in terms of preserving left ven-
tricular end-systolic and end-diastolic volumes, leading to increased
cardiac output and global function? Second, given that there are
different energy sources with TMR, do you think that there will
be a difference between a carbon dioxide laser and a Ho:YAG laser?
Dr Atluri. That was the big question we had to answer in decid-
ing on a laser. The three lasers to choose fromwere the excimer laser,
the carbon dioxide laser, and the Ho:YAG laser. The excimer laser is
not commercially available in theUnited States, although it is used in
Europe. Dr Hughes in Journal of the American College of Cardiol-
ogy back in 2002 presented his results in which he basically found
no difference between the excimer laser and sham treatment in terms
of angiogenesis or vascular density. The next decision was between
carbon dioxide and Ho:YAG. Dr Horvath in 2004 published some of
these results. The difference between aHo:YAG laser and carbon di-
oxide laser was marginal; nonetheless, there was enhanced vascular-
ity with a Ho:YAG laser. We theorized from its physical properties
that the Ho:YAG laser generated a greater area of inflammationwith-
out tissue destruction, thereby enhancing angiogenesis. That was our
thought process in picking our laser.
In terms of preservation of ventricular function or ventricular
volumes, if I understood your question correctly, some of the data
that we found in addition (because of time constraints we were un-
able to present all of our data) indicated that there was greater pres-
ervation of ventricular diastolic diameter with TMR. This
approached but did not reach statistical significance.racic and Cardiovascular Surgery c Volume 135, Number 2 291
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CDFigure E1. Therapy with transmyocardial laser revascularization
(TMR) enhances myocardial vasculature. Representative immuno-
fluorescent images of myocardium from ischemic left circumflex
coronary myocardium of animals in sham and transmyocardial
laser revascularization groups labeled for vasculature (green
for CD31) and nuclei (blue for 4',6-diamidino-2-phenylindole) are
demonstrated (original magnification 203; scale bar represents
50 mm).291.e1 The Journal of Thoracic and Cardiovascular Surgery c February 2008
